Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2019

  1. 08/07/2019
    MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
  2. 03/07/2019
    MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
  3. 03/07/2019
    Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
    No download available
  4. 24/06/2019
    Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  5. 24/06/2019
    MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
  6. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  7. 22/06/2019
    MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
  8. 14/06/2019
    MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
  9. 23/05/2019
    MorphoSys to Present at Upcoming Investor Conferences
  10. 22/05/2019
    MorphoSys AG Reports Outcome of Annual General Meeting 2019

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2019

  1. 03/07/2019
    Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
    No download available
  2. 24/06/2019
    Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  3. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  4. 16/05/2019
    MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
    No download available
  5. 19/02/2019
    Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
    No download available
  6. 26/01/2019
    Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
    No download available

2018

  1. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  2. 19/07/2018
    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
    No download available
  3. 18/04/2018
    Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
  4. 09/04/2018
    Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States

Pages

Presentations
and conferences

Archive

Date
Title
MP3

2019

  1. 06/25/2019

    Webcast: Meet the Team

  2. 06/22/2019

    Presentation: ICML in Lugano

  3. 06/12/2019

    Presentation: Goldman Sachs 40th Annual Global Healthcare Conference

  4. 06/06/2019

    Presentation: dbAccess

  5. 06/05/2019

    Webcast: Jefferies Healthcare Conference

  6. 05/20/2019

    Conference call: Q&A session on the headline data of tafasitamab (MOR208)

  7. 05/08/2019

    Conference Call and Webcast: Q1 2019 Financial Results

  8. 04/26/2019

    Presentation: Class of 2018 Biotech IPOs Investor Day

  9. 04/16/2019

    Presentation: Kempen Life Sciences Conference

  10. 03/14/2019

    Year-End 2018 Conference Call and Webcast

  11. 02/28/2019

    Webcast: 8th Annual Leerink Partners Global Healthcare Conference

  12. 01/21/2019

    Presentation: Kepler Chevreux German Corporate Conference

  13. 01/14/2019

    Presentation: Commerzbank German Investment Seminar 2019

  14. 01/09/2019

    Webcast: JPMorgan Annual Healthcare Conference 2019

2018

  1. 12/06/2018

    Presentation: Berenberg European Conference 2018

  2. 12/05/2018

    Webcast: Investor & Analyst Event

  3. 11/28/2018

    Presentation: Piper Jaffray Annual Healthcare Conference

  4. 11/26/2018

    Presentation: German Eigenkapitalforum

  5. 11/22/2018

    Presentation: Bryan Garnier 6th Annual Healthcare Conference

  6. 11/06/2018

    Conference Call and Webcast: Q3 2018 Financial Results

  7. 10/03/2018

    Webcast: Leerink Partners Roundtable Series: Rare Disease & Oncology

  8. 09/25/2018

    Presentation: Berenberg and Goldman Sachs Seventh German Corporate Conference

  9. 09/24/2018

    Presentation: Baader Investment Conference

  10. 09/07/2018

    Presentation: Goldman Sachs Eighth Annual Biotech Symposium

  11. 08/28/2018

    Presentation: Commerzbank Sector Conference

  12. 08/02/2018

    Conference Call and Webcast: Q2 2018 Financial Results

Pages

Pictures

Management Board

Dr. Simon E. Moroney

Chief Executive Officer,
MorphoSys AG

Jens Holstein

Chief Financial Officer,
MorphoSys AG

Dr. Malte Peters

Chief Development Officer,
MorphoSys AG

Dr. Markus Enzelberger

Chief Scientific Officer,
MorphoSys AG

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".